Home / Market News / $HIMS
fiscal.ai Corporate Catalyst Impact 92/100 ● negative

Hims & Hers Health Reports Q3 2026 Financial Results and Updates 2026 Outlook

Nov 9, 2026, 11:08 PM UTC · Primary ticker $HIMS

Hims & Hers Health reported Q3 2026 financial results that missed analyst expectations for both revenue and earnings per share. The company also lowered its full-year 2026 revenue guidance, indicating a potential slowdown in growth or increased competitive pressures, which is likely to be a significant negative catalyst for the stock.

Hims & Hers Health announced Q3 2026 results that fell short of FactSet consensus estimates for both revenue ($890.4M vs. $893.1M) and EPS (loss of $0.14 vs. expected loss of $0.06). More critically, the company revised its full-year 2026 revenue guidance downwards to $3.13B-$3.15B from the previous FactSet estimate of $3.21B. This dual miss and guidance cut signals potential headwinds for the company, impacting investor confidence. Short-term, HIMS stock is likely to experience significant downward pressure as the market digests the weaker-than-expected performance and outlook. Long-term implications depend on whether this is a temporary blip or indicative of broader challenges in its growth strategy or market competition. Traders should watch for analyst downgrades and revised price targets.

$HIMS negative Missed Q3 revenue/EPS, lowered FY26 guidance
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.